Extended Data Fig. 4: Interferon-induced protein validation and liver sources of interferons. | Nature Immunology

Extended Data Fig. 4: Interferon-induced protein validation and liver sources of interferons.

From: Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis

Extended Data Fig. 4

Box plot by cell type per patient of average (a) ISG score per disease stage (NS-SS (n = 6), early MASH (n = 10), advanced MASH (n = 9)) in liver FNA (left) and PBMCs (right), (b) IFNG expression in liver FNAs (n = 25), and (c) upstream gene expression for interferon-alpha (left) and interferon-beta (right) in liver FNAs (n = 25): data are presented as median values (horizontal line), 25th/75th quartile values (bounds of boxes), and non-outlier minimum/maximum (whiskers); two-sided Wilcoxon; upstream genes are shown in Extended Data Table 2. (d) Magnification of Extended Data Fig. 3a: box plot of the percentage of pDCs out of each sample in FNA (left) and PBMC (right): data presented as in 5a; two-sided permutation test; significance (*) determined by false-discovery rate (FDR) < 0.05 and log2 false discovery (log2FD)>0.58. (e) Comparative ISG expression in liver monocytes (left) and macrophages (right) between patients without steatosis or with steatosis (NS-SS), those with MASH and those with untreated HCV: data are presented as median values (horizontal line); two-sided Wilcoxon; ***P < .001. (f) Immuno-fluorescent (IF) validation of MX1 and IFIT3 in macrophages in human liver tissue biopsies. Representative image merged and per channel (left) and expression fractions of MX1 + , IFIT3 + , and MX1 + IFIT3+ out of macrophages (CD68 + ) for three disease stages (right): simple steatosis (SS, n = 1), early MASH (F1, n = 1), and advanced MASH (F2, n = 1).

Back to article page